AU4403885A - Creación de Inventos y Patentes con Inteligencia Artificial

AU4403885A – An efficient process for producing active chymosin from a precursor protein synthesized in bacteria
– Google Patents

AU4403885A – An efficient process for producing active chymosin from a precursor protein synthesized in bacteria
– Google Patents
An efficient process for producing active chymosin from a precursor protein synthesized in bacteria

Info

Publication number
AU4403885A

AU4403885A
AU44038/85A
AU4403885A
AU4403885A
AU 4403885 A
AU4403885 A
AU 4403885A
AU 44038/85 A
AU44038/85 A
AU 44038/85A
AU 4403885 A
AU4403885 A
AU 4403885A
AU 4403885 A
AU4403885 A
AU 4403885A
Authority
AU
Australia
Prior art keywords
protein
chymosin
gene product
solubilizing
precursor protein
Prior art date
1984-05-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Application number
AU44038/85A
Inventor
John F. King
Michael T. Mccaman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Codon Genetic Engineering Laboratories

Original Assignee
Codon Genetic Engineering Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1984-05-11
Filing date
1985-05-08
Publication date
1985-12-13
Family has litigation

First worldwide family litigation filed
litigation
Critical
https://patents.darts-ip.com/?family=24441051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU4403885(A)
«Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1985-05-08
Application filed by Codon Genetic Engineering Laboratories
filed
Critical
Codon Genetic Engineering Laboratories

1985-12-13
Publication of AU4403885A
publication
Critical
patent/AU4403885A/en

Status
Abandoned
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes

C12N9/14—Hydrolases (3)

C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)

C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue

C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals

C12N9/6478—Aspartic endopeptidases (3.4.23)

C12N9/6481—Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length

C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides

C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure

C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents

Abstract

A process for producing active chymosin from an insoluble chymosin precursor protein. The process comprises solubilizing the precursor protein in a solubilizing reagent capable of solubilizing the protein and removing the reagent whereby the protein assumes a thermodynamically stable and biologically active conformation.

Description

Description
An Efficient Process for Producing Active Chymosin from a Precursor Protein Synthesized in Bacteria
Technical Field of Invention The present invention relates to the restoration of biological activity to inactive proteins, that is solubilizing, renaturing and restoring activity to proteins which have been partially denatured or inactivated, e.g. during their synthesis in a host cell, such as E_;_ coli, or during isolation. In particular it relates to an efficient process for producing active chymosin from an insoluble chymosin precursor isolated from genetically engineered bacteria.
Background of the Invention
With the advent of recombinant DNA technology, it is now possible to introduce foreign genes into microorganisms and regulate the level of their expression. However, the synthesis of an excess of polypeptide or protein not endogenous to the bacterium may have an adverse effect on the organism’s viability, especially if produced at a high level relative to other host proteins. In some instances, the host organism may have a mechanism of disposing of the cloned gene product, e.g. by degrading it or secreting it, thus avoiding interaction with the essential metabolic machinery of the cell. Alternatively, the cloned gene product may assume an altered conformation, thus limiting its interference with normal cellular processes. Disruption or alteration of normal translational or post-translational events, the specific codon usage pattern during protein synthesis.

and/or host protein-cloned gene product interactions within the cell, may also effect the polypeptide’s normal folding and assembly and may result in an inactive conformation of the protein. In a host ~~ organism such as E_^ coli it has been observed in several cases that foreign proteins fold unnaturally and precipitate within the cell to form large inactive protein aggregates, characterized as inclusion bodies (Williams, D. C, et al. Science 215:687-689 (1982) and Kleid, D. G., et al. Science 2_1 :1125-1128 (1981)). It has been shown that native (active) proteins can undergo reversible denaturation (Anfinsen, C. , Science 181:223-230 (1973) and London, J. et al., Eur. J. Biochemistry £7:409-415 (1974). The protein is denatured by addition of 8 molar urea and polypeptide refolding occurs spontaneously as the urea is removed. Alkali solutions have also been used as protein solubilizing agents and in some cases can reversibly denature native proteins during brief incubation times (McPhie, P. J. of Biol. Chem 257:689-693 (1982)’.» ‘
Urea has also been used to aid in the renaturaion of the gene product of a recombinant DNA expression system (Emtage, J. S. e^ al. , Proc. Nat. Acad. Sci. USA 80_:3671-3675 (1983)).
Summary of the Invention
The present invention provides a process for producing active chymosin from an insoluble chymosin precursor protein comprising solubilizing said protein in a solubilizing reagent capable of so solubilizing the protein and removing the reagent whereby the protein assumes a thermodynamically stable and biologically active conformation. Characteristically, the protein which is isolated from its host cell, e_.£. , E. coli, differs in its physical and chemical characteristics from the same protein isolated from its

natural environment (calf stomach procnymosin) . The same physical and chemical characteristics of the isolated protein are caused to duplicate those of the naturally occurring product by practicing the present invention, that is, by solubilizing the inactive or denatured gene product in a suitable solubilizing reagent and removing the reagent in a manner which allows the polypeptide to assume a thermodynamically stable form possessing its natural biological activity. An aspect of the present invention discloses novel processes for producing active chymosin, utilizing Triton X-100 (a non-ionic detergent) as a reagent for protein purification and urea and alkali as reagents for solubilization and renaturation. Thus the present invention is a novel and original procedure for protein renaturation.
A recombinant DNA expression system, and its host microorganism, used as an example in an embodiment of the present invention and described as JM83/pLC7 was deposited with the American Type Culture Collection-, Rockville, Maryland and assigned the accession number ATCC 39325.
Brief Description of the Figures
Figure 1 shows an electron micrograph cross- section of E^ coli cells (a) containing prochymosin inclusion bodies (arrows) and (b) wild type bacteria which do not contain inclusion bodies.
Figure 2 shows the recovery of milk clotting activity derived from ρWHA*49 prochymosin after solubilization and renaturation by two of the processes disclosed in this invention. The observed activity per volume is plotted against the dilution factor (material from 1 gram of cell paste/final volume in mis) at which the renaturation reaction was performed.

Figure 3 shows a polyacrylamide gel containing protein samples derived from E^ coli synthesizing prochymosin, wherein the samples include: total cell proteins from parental E. coli strain CY15001 (lane l); total cell proteins from prochymosin expression strain CYl5001/pWHA49 (lane 2); purified and renatured pWHA49 prochymosin (lane 3); purified and renatured pWHA49 prochymosin after pH 2.0 activation (lane 4); purified and renatured pWHA49 prochymosin after pH 4.5 activation (lane 5); purified calf prochymosin (lane 6); purified calf prochymosin after activation at pH 2.0 (lane 7); and purified calf prochymosin after activation at pH 4.5 (lane 8).
Figure 4 shows a polyacrylamide gel containing protein samples derived from a milk substrate before and after reaction with chymosin derived from either calf or pWHA49 prochymosin, wherein the samples include: molecular weight markers (lane 1); unreacted milk substrate (lane 2); milk coagulated with pWHA49 -pseudochymosin (lane 3); milk coagulated with pWHA-4-9 chymosin (lane 4); milk coagulated with calf chymosin (lane 5); and milk substrate coagulated with trypsin (lane 6). The arrow indicates K-casein protein component cleaved by chymosin.to initiate coagulation reaction.
Detailed Description of the Invention
The present invention is particularly directed to the production of active chymosin from a chymosin precursor protein isolated in an insoluble, inactive and/or partially denatured state from E^ coli (see Figure 1). The term «denatured» is intended to describe the form of the protein whose conformation and biological activity differs significantly from the same protein isolated from its natural environment. The details of the process are described below.

A bacterial cell paste is resuspended in a buffer containing lysozyme and as cell lysis occurs the viscosity of the solution increases due to the bacterial DNA. For the present invention, it is important to reduce the viscosity of the lysate by physical methods such as sonic disruption of the DNA or use of a French press. The insoluble fraction of the cell is isolated by low speed centrifugation. The insoluble fraction is resuspended in buffer and mixed with a solution containing Triton X-100 (a non-ionic detergent) for 2-20 hours. This detergent does not solubilize the chymosin precursor protein but does solubilize other bacterial protein contaminants. These contaminants are separated and removed from the insoluble chymosin precursor protein by centrifugation. The insoluble fraction is solubilized in 8M urea for 2-20 hours, preferably 10-16 hours and then diluted into an alkaline phosphate buffer preferably pH 10.5- 11.5, and most preferably pH 11.0, incubated .for 5-30 minutes, most preferably 10 minutes, and then neutralized slowly to a pH of 8-9, preferably 8.3 and allowed to stand for one hour or more. Subsequent acidification to a pH less than 5 resulted in the generation of a milk clotting activity whose properties are the same as calf stomach chymosin.
The present invention requires several specific steps to achieve efficient recoveries of active chymosin. First, the combination of sonication (after cell lysis) and Triton X-100 extraction (after collecting the insoluble proteins by centrifugation) are essential to this process.
Table I, infra, illustrates the relative effectivesness in recovery of active chymosin from various precursor renaturation procedures.

Table I
Chymosin Recovery After Various Precursor Renaturation Schemes
Disruption Method «» Sonication Enzyme Treatment
Insoluble fraction from cell lysate 7%
Buffer washed insoluble fraction 1% 36% Insoluble fraction after extraction with Triton X-100 100% 31%
Insoluble fraction after extraction with Tween-20 1%
As seen in Table I only low levels of active product (less than 10% of maximal) can be recovered if the Triton X-100 extraction is omitted. The substitution of another «non-ionic detergent, Tween-20, does not facilitate the recovery of high levels of active product. Reducing the vicosity of the initial cell lysate by enzymatic. digestion of the bacterial DNA with pancreatic DNase results in low yields of activity from the chymosin precursor protein after its activation and these product yields are not improved by a Triton X-100 extraction step. Thus, the combination of physical disruption of the bacterial lysate (by sonication) followed by extraction with Triton X-100 is a novel and unexpected requirement for the present invention.
The second essential feature of this process is the combined use of urea and alkaline pH buffer to solubilize and renature the chymosin precursor protein. Complete solubilization of the insoluble chymosin precursor protein can occur in 8M urea or alkali alone. However, the use of each of these reagents alone have several disadvantages. Solubilization with urea is very rapid but renaturation from urea requires a dialysis step which

is very slow. Solubilization with alkali is slower than with urea and is complicated by an irreversible inactivation of the protein which begins after 20 minutes of incubation at pH 11.0 which is approximately the—‘time required for complete solubilization of the chymosin precursor protein. Rapid renaturation from alkaline pH can be achieved by acidification. By simply combining these two procedures we observed a significant improvement in chymosin activity recovered in the final product (see Figure 2). The rapid solubilization in urea is combined with dilution in an alkaline pH buffer and rapid renaturation occurs by a pH neutralization. The successful renaturation of purified calf prochymosin is dependent on prochymosin concentration during the renaturation reaction. Likewise, a more efficient recovery of active chymosin from the insoluble chymosin precursor isolated from E_^ coli is dependent on the extent of dilution of the urea solubilized material into the alkaline pH buffer (see Figure 4). The maximal level of chymosin activity achieved by the present – invention is greater than or equal to 80% of the predicted limit based upon our estimates of chymosin precursor protein levels in the ^_ coli lysate and the known specific activity of calf stomach chymosin.
Experimental
A plasmid pWHA49 was constructed which contains a eukaryotic structural gene coding for prochymosin. This plasmid was used to transform E^ coli using known techniques. lOg of frozen cell paste of E^ coli strain CY15001 containing pWHA49 were suspended in 100 mis of 25 mm Tris-HCl pH 8, 10 mm EDTA, 1 mg/ml lysozyme. After a short incubation, the lysed cells were further disrupted by sonication. Partial purification of the pWHA49 encoded prochymosin protein was effected by

centrifugation at 10,000 x for ten minutes, followed by an overnight detergent extraction of the pelleted cell debris with 8 percent final concentration of Triton X-100 detergent (Sigma Chemical Co.). The pWHA49 prochymosin protein remained in the insoluble, particulate pellet after the procedure.
Authentic calf prochymosin is a soluble enzyme which can be rapidly activated by acid treatment to a form which efficiently coagulates milk. The E_^ coli synthesized pWHA49 prochymosin, isolated as described, was insoluble and showed no enzymatic activity after acid treatment.
The pWHA49 prochymosin pellet was suspended in 6.3 mis of 10 mM sodium phosphate buffer at pH 7.5. The suspension is fully solubilized by the addition of solid urea to a final concentration of 6-8 M and then mixed for 16 hours at room temperature.
The resultant clear solution was diluted into 100 volumes (1000 mis) of 25 mM sodium phosphate buffer at pH 11.0, mixed thoroughly and allowed to stand for 10 minutes at room temperature. The pH of the solution was then titrated to pH 8.3 by addition of 0.2N HC1 over a period of 3 minutes.
The resultant solution was left at room temperature for one hour or more, after which time acidification to a pH greater than 1.5 and less than 5.0 generated a chymosin milk clotting activity. Acid activation of native calf prochymosin and of pWHA49 prochymosin resulted in the same size proteins, that is, treatment at pH 2 produced pseudochymosin having a molecular weight of approximately 38,500 and treatment at pH 4.5 produced chymosin at a molecular weight of 36,000 (see Figure 3). The renatured, activated product has 50-95 percent of the specific activity of natural calf chymosin and has the same limited substrate specificity (see Figure 4).

The process utilizing urea and alkali demonstrated improvements in renaturing prochymosin, when compared to methods using a single reagent (see Figure 2).

Claims (13)

Claims

1. A process for restoring biological activity to a cloned gene product comprising solubilizing an inactive gene product in a solubilizing reagent capable of so solubilizing the product and thereafter removing the reagent, whereby the product assumes a thermodynamically stable and biologically active conformation.

2. The process of claim 1 wherein said solubilizing reagent comprises a mixture of distinct agents.

3. The process of claim 1, further comprising treating said gene product sequentially with a plurality of distinct agents.

4. The process of claim 3 wherein the cloned gene product comprises a protein initially isolated in an inactive state from E. coli.

5. The process of claim 3 wherein the inactive gene product comprises a protein which differs in its physical and chemical characteristics from the same protein isolated from its natural environment.

6. The process of claim 3 further comprising separating the inactive gene product from insoluble material by extraction with a detergent solution.

7. The process of claim 6 wherein said detergent solution contains Triton X-100.

8. The process of claim 3 wherein said distinct solubilizing agents comprise a chaotropic agent and alkali.

9. The process of claim 8 wherein said alkali comprises a member selected from the group consisting of sodium hydroxide and potassium hydroxide.

10. The process of claim 8 wherein said choatropic agent is urea.

11. The process of claim 1 wherein the cloned gene product is a chymosin precursor protein.

12. The process of claim 9 wherein the chymosin precursor protein is methionine-prochymosin.

13. Enzymatically active chymosin produced by process of any of the preceding claims.

AU44038/85A
1984-05-11
1985-05-08
An efficient process for producing active chymosin from a precursor protein synthesized in bacteria

Abandoned

AU4403885A
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

US60949584A

1984-05-11
1984-05-11

US609495

1984-05-11

Publications (1)

Publication Number
Publication Date

AU4403885A
true

AU4403885A
(en)

1985-12-13

Family
ID=24441051
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU44038/85A
Abandoned

AU4403885A
(en)

1984-05-11
1985-05-08
An efficient process for producing active chymosin from a precursor protein synthesized in bacteria

Country Status (7)

Country
Link

EP
(1)

EP0183776B2
(en)

JP
(1)

JPH082298B2
(en)

AT
(1)

ATE71147T1
(en)

AU
(1)

AU4403885A
(en)

CA
(1)

CA1335719C
(en)

DE
(1)

DE3585081D1
(en)

WO
(1)

WO1985005377A1
(en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4786501A
(en)

1985-07-15
1988-11-22
International Minerals & Chemical Corp.
Cylindrical implants for the controlled release of growth hormones

Family Cites Families (6)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4666847A
(en)

1981-01-16
1987-05-19
Collaborative Research, Inc.
Recombinant DNA means and method

IE53517B1
(en)

1981-06-17
1988-12-07
Celltech Ltd
Process for the production of a polypeptide

BR8205954A
(en)

1981-10-14
1983-09-13
Unilever Nv

DNA SEQUENCE, RECOMBINANT PLASMIDIUM, BACTERIAL CULTURE AND MICROORGANISMS

FI841288A
(en)

1983-03-31
1984-10-01
Codon Genetic Eng Lab

RECOMBINANT DNA CODE FOR UTTRYCKNING AV POLYPEPTIDES.

US4721673A
(en)

1983-09-01
1988-01-26
Genex Corporation
Recovery and activation process for microbially produced calf prochymosin

JPH082298A
(en)

1994-06-16
1996-01-09
Araco Corp
Seat cushion length variable mechanism

1985

1985-05-08
WO
PCT/US1985/000858
patent/WO1985005377A1/en
active
IP Right Grant

1985-05-08
AU
AU44038/85A
patent/AU4403885A/en
not_active
Abandoned

1985-05-08
DE
DE8585902779T
patent/DE3585081D1/en
not_active
Expired – Fee Related

1985-05-08
JP
JP60502346A
patent/JPH082298B2/en
not_active
Expired – Fee Related

1985-05-08
AT
AT85902779T
patent/ATE71147T1/en
not_active
IP Right Cessation

1985-05-08
EP
EP85902779A
patent/EP0183776B2/en
not_active
Expired – Lifetime

1985-05-10
CA
CA000481224A
patent/CA1335719C/en
not_active
Expired – Fee Related

Also Published As

Publication number
Publication date

JPH082298B2
(en)

1996-01-17

ATE71147T1
(en)

1992-01-15

DE3585081D1
(en)

1992-02-13

WO1985005377A1
(en)

1985-12-05

EP0183776B1
(en)

1992-01-02

EP0183776A1
(en)

1986-06-11

JPS61502167A
(en)

1986-10-02

EP0183776B2
(en)

2000-09-13

EP0183776A4
(en)

1988-05-19

CA1335719C
(en)

1995-05-30

Información de contacto